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Osteoarthritis and smouldering synovitis
Although it is generally accepted that the primary eﬀ ect 
of stem cell treatment occurs through tissue-speciﬁ c 
diﬀ erentiation, new data suggest that the therapeutic 
potential of these cells might also be related to their 
paracrine eﬀ ect [1,2].
Clinically, patients with osteoarthritis (OA) express 
variable synovitis. Th ickening of the lining layer con-
taining predominantly macrophages that exhibit an 
activated phenotype is found within a substantial sub-
popu lation of OA patients. Synovial macrophages produce 
elevated levels of pro-inﬂ ammatory factors like cytokines 
(IL-1), complement factors and damage-associated 
molecular pattern molecules (DAMPs;S100A8/A9) [3].
Release of cartilage matrix fragments from damaged 
cartilage may give a prolonged stimulation of synovial 
macrophages, thereby forming a positive feedback loop 
that drives smouldering synovitis. Previous studies have 
shown that selective elimination of synovial macrophages 
prior to induction of experimental murine OA prevented 
synovial activation and development of joint destruction 
like cartilage destruction and new formation of cartilage/
bone (osteophytes). Synovial macrophages may contri-
bute to cartilage destruction by prolonged production of 
pro-inﬂ ammatory cytokines or to new formation of 
osteophytes by release of growth factors [4].
Adipose-derived stem cells express 
anti-infl ammatory characteristics
Adipose tissue hosts multipotent stem cells that can easily 
be puriﬁ ed by digestion and adhesion to plastic surfaces 
and shares numerous properties with bone marrow-
derived mesenchymal stem cells (MSCs). Five percent of 
the nucleated fraction in adipose tissue represents stem 
cells, which is far more than found in adult human bone 
marrow. Adipose-derived stem cells (ADSCs) have been 
shown to exhibit immune suppressive properties and 
release anti-inﬂ ammatory molecules like IL-10, IL-1 recep-
tor antagonist (IL-1ra), indoleamine 2,3-dioxygenase, trans-
forming growth factor (TGF)β and prostaglandin E2 [5]
Desando and colleaques [1] induced OA through 
bilateral anterio cruciate ligament transsection, which 
causes thickening of the lining layer. A single local 
administration of ADSCs into such an OA knee joint 
attenuated inﬂ ammation in the synovial membrane and 
was reﬂ ected by less thickening of the lining layer and 
lowering of matrix metalloproteinase-1 expression. 
Interest ingly, labelled ADSCs were detected within the 
synovial layer in close contact with synovial macrophages.
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In recent studies it was found that MSCs express an 
elevated immunosuppressive action when applied to 
inﬂ ammatory regions, suggesting that factors released 
during inﬂ ammation do interact with stem cells, driving 
their immunosuppressive capacity. Up till now the 
immune modulatory properties have been clearly detected 
after treatment of acute graft versus host disease and 
autoimmune diseases. First, the focus was on T cells but 
later on it was found that MSCs also block the generation 
of functional antigen-presenting cells like macrophages. 
So MSCs not only inhibit the adaptive immune response 
but also cells of innate immunity, including macrophages 
[5].
MSCs can induce polarization towards ‘alternative 
activated’ M2 cells characterized by a high expression of 
CD206 and release of cytokines like IL-10 and lower 
IL-12 and TNFα production. Th e immunomodulatory 
function of ADSCs is strongly elevated by cytokines such 
as interferon-γ, TNFα and IL-1α/β, which are produced 
by activated macrophages. Th ese cytokines strongly 
elevate the production of suppressive factors [6,7]. Th e 
immunosuppressive activity is thus not a constitutive 
property of MSCs but depends on a process of activation 
or licensing.
Intra-articular deposition of ADSCs protects 
against joint destruction during experimental OA
Desando and colleagues further found that a single 
injection of ADSCs into OA rabbit knee joints protected 
against development of cartilaginous and meniscal 
damage. Th is is in line with a previous study in our lab in 
a murine osteoarthritis model, where intra-articular 
injection of collagenase resulted in ligament damage and 
instability-related OA cartilage damage, along with 
marked synovial thickening. In that study, injected 
ADSCs closely interacted with synovial macrophages and 
inhibited ligament damage and development of joint 
destruction at later time-points [8]. Apart from inhibition 
of pro-inﬂ ammatory cytokines by macrophages, ADSCs 
may also stimulate macrophages to produce elevated 
levels of growth factors.
Osteophytes and synovial activation
During OA, new formation of cartilage/bone (osteo-
phytes) is found in locations at the joint margins. Intra-
articular injection of growth factors like TGFβ or bone 
morphogenetic protein-2 can mimic this process and 
show characteristic patterns [9]. Interestingly, when the 
synovial lining layer was depleted from macrophages 
prior to injection of TGFβ, osteophyte formation was 
greatly reduced, suggesting that TGFβ acts via activation 
of macrophages [10]. So, ADSCs may inhibit macro-
phages to produce TGFβ-regulated factors that are 
crucial for mediating osteophyte formation.
In summary, recent studies performed in animal OA 
models show that a single local administration of ADSCs 
into OA joints induces suppression of synovial activation, 
and ameliorates damage of the ligaments and menisci, 
thereby inhibiting development of cartilage destruction 
and new formation of cartilage/bone. Th e immuno-
suppressive phenotype of the ADSCs may thereby be 
driven by pro-inﬂ ammatory factors released by the 
synovium. Recently started studies in OA patients will 
soon provide an answer to the question of whether this 
application will also help to prevent joint destruction 
within the human OA joint. Special attention needs to be 
given to subtypes of OA bearing an inﬂ ammatory 
component.
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